Abstracts tagged "interleukins (IL)"

Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Atul Deodhar¹, Ricardo Blanco ², Eva Dokoupilova ³, Marleen van de Sande ⁴, Stephen Hall ⁵, Anna Wiksten ⁶, Brian Porter ⁷, Hanno Richards ⁶, Sibylle Haemmerle ⁶ and Jürgen Braun ⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, ⁴Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, ⁵Monash University, Melbourne, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Mahamudul Haque¹, Madeline McDougal ¹, Anil Singh ¹ and Salahuddin Ahmed ², ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Diamant Thaçi ¹, Kristian Reich ², Jo Lydie Lambert ³, Lars Iversen ⁴, Andrea Peserico ⁵, Ignasi Pau-Charles ⁶, Andrew Blauvelt⁷ and Christopher Griffiths ⁸, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ³Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁴Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁵Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, ⁶Almirall R&D, Barcelona, Spain, Barcelona, Spain, ⁷Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁸Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
Abstract Number: 111 • 2019 ACR/ARP Annual Meeting
The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles
Catherine Poholek¹, Itay Raphael ² and Mandy McGeachy ², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Th17 lineage of CD4 T cells drives autoimmune diseases such as RA, SLE, IBD, and MS. The JAK2/STAT3 signaling pathway is required for…
Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Burkhard Moeller¹, Eleftherios Papagiannoulis ², Lisa Christ ³, Adrian Ciurea ⁴, Thomas Hugle ⁵, Ruediger B. Mueller ⁶, Michael J. Nissen ⁷, Almut Scherer ⁸, Godehard Scholz ³, Peter M. Villiger ¹ and Nikhil Yawalkar ³, ¹University Hospital Bern, Bern, Switzerland, ²SCQM Zurich, Zurich, Switzerland, ³Inselspital-University Hospital Bern, Bern, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵University Hospital Lausanne, Lausanne, Switzerland, ⁶Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ⁷University Hospital Geneva, Geneva, Switzerland, ⁸SCQM Foundation, Zürich, Switzerland
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
Abstract Number: 112 • 2019 ACR/ARP Annual Meeting
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Sushmita Chakraborty ¹, Ranjan Gupta ², Rinkee Kumari ¹ and Dipendra Kumar Mitra¹, ¹All India Institute of Medical Sciences, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: 950 • 2019 ACR/ARP Annual Meeting
Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease
Xiao-qing Liu¹, Xiaojie Liu ², Nalin Lai ³, Ting Cheng ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²Taiyuan University of Technology, Taiyuan, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies…
Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Philip Mease¹, Laure Gossec ², Laura Coates ³, Alice B. Gottlieb ⁴, Deepak Assudani ⁵, Barbara Ink ⁵, Jason Coarse ⁶, Oscar Irvin-Sellers ⁵ and Dafna Gladman ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, ⁵UCB Pharma, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁷Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Helena Marzo-Ortega¹, Corinne Miceli-Richard ², Sonja Gill ³, Marina Magrey ⁴, Paula Machado ⁵, Abhijit Shete ⁶, Jianyuan Wang ⁶, Susanne Rohrer ⁶ and Atul Deodhar ⁷, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto¹, Negin Shojaee ¹, Ravi Shankar P Singh ¹, Zorayr Manukyan ², Jessica Mancuso ¹, Elena Peeva ¹, Michael Vincent ¹ and Jean Beebe ¹, ¹Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, ²Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes¹, Dafna Gladman ², Atul Deodhar ³, Corinne Miceli-Richard ⁴, Peter Nash ⁵, Naveed Sattar ⁶, Nehal Mehta ⁷, Darren Asquith ⁸, Jianyuan Wang ⁹, Hanno Richards ⁹, Luminita Pricop ¹⁰ and Abhijit Shete ⁹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Oregon Health & Science University, Portland, OR, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁸Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Alan Menter ¹, Zoe Draelos ², Jayme Heim ³, Jeff Parno ⁴, Alan Mendelsohn⁴, Stephen Rozzo ⁴ and Christopher Griffiths ⁵, ¹Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, ²Dermatology Consulting Services, High Point, NC, USA, High Point, NC, ³West Michigan Dermatology, Holland, MI, USA, Holland, MI, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Alice Gottlieb ¹, Ana-Maria Orbai ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Luis R. Espinoza ⁵, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].